Drug Profile
Sodium pyruvate - EmphyCorp
Alternative Names: EmphyClear COPD Oral Spray; EmphyClear COPD/Asthma Spray; N115; N115 Non-Steroidal Nasal Spray; Rx N115 non-steroidal nasal spray; Sodium pyruvate inhalation - EmphyCorp; Sodium pyruvate nasal sprayLatest Information Update: 28 Apr 2023
Price :
$50
*
At a glance
- Originator Emphycorp
- Developer Cellular Sciences; Emphycorp
- Class Antiasthmatics; Antifibrotics; Antivirals; Sodium compounds
- Mechanism of Action Interleukin 6 inhibitors; Reactive oxygen species inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase III Interstitial lung diseases
- Phase II/III COVID 2019 infections; Influenza virus infections; Post acute COVID 19 syndrome
- Phase II Asthma; Chronic obstructive pulmonary disease; Cystic fibrosis
- No development reported Lung disorders
Most Recent Events
- 28 Apr 2023 No recent reports of development identified for clinical-Phase-Unknown development in COVID-2019-infections(Prevention) in USA (Inhalation, Spray)
- 12 Aug 2022 Cellular Sciences completes a phase-II/III trial in COVID-2019 infections in USA (Inhalation, In adults) (NCT04824365)
- 12 Aug 2022 Cellular Sciences completes a phase-II/III trial in Influenza virus infections in USA (Inhalation, In adults) (NCT04824365)